Welcome to our dedicated page for FATE THERAPEUTICS SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FATE THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FATE THERAPEUTICS's regulatory disclosures and financial reporting.
Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they collectively hold 2,274,020.09 shares of Fate Therapeutics common stock, representing 2.0% of the class. The cover pages report shared voting power of 2,273,623.09 shares and shared dispositive power of 2,274,020.09 shares.
The filing includes a joint filing agreement (Exhibit 99.1) and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. (Exhibit 99.2). The filing further certifies the securities are held in the ordinary course of business and not for the purpose of changing control. The statement is signed by Veronica Mupazviriwo as attorney-in-fact on behalf of both reporting persons.
Fate Therapeutics (FATE) reported that on August 7, 2025 its Board approved a corporate restructuring to streamline operations, reduce operating expenses and extend the company’s cash runway. The company committed to a reduction in total workforce of approximately 12% and informed affected employees on August 12, 2025.
The company expects the reduction-in-force to complete in the third quarter of 2025 and estimates it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs. A press release with the quarter-end results is attached as Exhibit 99.1, and the information is furnished, not filed, under the Exchange Act.